Form 4: Adverum Biotechnologies Director Increases Stake Through Open Market Purchases

Director Braden Michael Leonard increases his indirect holdings in Adverum Biotechnologies through purchases made by BML Investment Partners, L.P.

Summary

• On March 31, 2025, Braden Michael Leonard, a director of Adverum Biotechnologies, indirectly acquired 19,566 shares of common stock at a weighted average price of $4.3784 per share.
• On April 2, 2025, Leonard indirectly acquired an additional 15,209 shares at a weighted average price of $4.0376 per share.
• These purchases were made through BML Investment Partners, L.P., where BML Capital Management, LLC serves as the general partner and Leonard is the managing member.
• Following these transactions, Leonard's indirect holdings total 2,757,526 shares through BML Investment Partners, L.P., and he directly owns 141,800 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed favorably, but the filing itself is a routine disclosure.

Positives

• The director's increased investment could signal confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive sign, suggesting that those with the most knowledge of the company's prospects are optimistic about its future.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, Director, Insider Trading, Beneficial Ownership, Stock Purchase, BML Investment Partners, Leonard